Cartesian Therapeutics Files 8-K

Ticker: RNAC · Form: 8-K · Filed: Nov 13, 2025 · CIK: 1453687

Cartesian Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyCartesian Therapeutics, Inc. (RNAC)
Form Type8-K
Filed DateNov 13, 2025
Risk Levellow
Pages6
Reading Time7 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, filing, financials

TL;DR

Cartesian Therapeutics filed an 8-K, likely with financial updates. Keep an eye out for details.

AI Summary

On November 13, 2025, Cartesian Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates that Cartesian Therapeutics, Inc. is providing updated information to the SEC, which could include material disclosures about the company's operations or financial status.

Risk Assessment

Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific material information that would inherently increase risk.

Key Players & Entities

  • Cartesian Therapeutics, Inc. (company) — Registrant
  • November 13, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • 001-37798 (identifier) — Commission File Number
  • 7495 New Horizon Way, Frederick, MD 21703 (address) — Address of principal executive offices
  • 301-348-8698 (phone_number) — Registrant's telephone number

FAQ

What specific events or financial information are disclosed in this 8-K filing?

The provided excerpt indicates the filing pertains to 'Regulation FD Disclosure', 'Other Events', and 'Financial Statements and Exhibits', but does not detail the specific content of these disclosures.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on November 13, 2025.

What is the Commission File Number for Cartesian Therapeutics, Inc.?

The Commission File Number for Cartesian Therapeutics, Inc. is 001-37798.

Where are Cartesian Therapeutics, Inc.'s principal executive offices located?

Cartesian Therapeutics, Inc.'s principal executive offices are located at 7495 New Horizon Way, Frederick, MD 21703.

What is the IRS Employer Identification Number for Cartesian Therapeutics, Inc.?

The IRS Employer Identification Number for Cartesian Therapeutics, Inc. is 26-1622110.

Filing Stats: 1,844 words · 7 min read · ~6 pages · Grade level 17.3 · Accepted 2025-11-13 16:08:56

Key Financial Figures

  • $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC Ind

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure Descartes-08 SLE Data and Myositis Indication On November 13, 2025, Cartesian Therapeutics, Inc. (the "Company") issued a press release announcing initial data from its ongoing Phase 2 open-label trial of Descartes-08 in participants with systemic lupus erythematosus ("SLE") and its planned expansion of Descartes-08 into myositis. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. Corporate Presentation The Company from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. A copy of the Company's corporate slide presentation highlighting the initial SLE data and the Company's planned expansion of Descartes-08 into myositis is attached hereto as Exhibit 99.2 and incorporated herein by reference. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events On November 13, 2025, the Company announced initial data from its ongoing Phase 2 trial of Descartes-08 in participants with SLE. The Phase 2 open-label trial was designed to evaluate outpatient administration of Descartes-08 without preconditioning chemotherapy or integrating vectors for the treatment of participants with moderate or severe SLE refractory to immunosuppressant therapy. The primary outcome measure assesses safety and tolerability, with secondary outcome measures assessing preliminary efficacy. Initial data reported significant reduction in disease activity following initial Descartes-08 treatment with 100% of participants who reached Month 3 follow-up (n=3) achieving Lupus Low Disease Activity State (LLDAS) response, defined by specific criteria that indicate low disease activity, improved patient outcomes, and sustained symptom improvement. A fourth patient has not yet reached Month 3 as of November 13, 2025. These results further validate the clinical effect of Descartes-08 in the field of autoimmune disease and the Company will continue to analyze the data from SLE to determine the next steps for the program. Disease remission reported as DORIS response was seen in two out of three participants at Month 3. DORIS is defined as the Definition of Response in SLE indicating a clinical SLE Disease Activity Index (SLEDAI)-2K score of 0 and physician global assessment (PGA) of less than 0.5. Descartes-08 continues to be observed as well-tolerated, supporting outpatient administration without the need for lymphodepleting chemotherapy. Adverse events were transient and mostly mild, and notably, there were no cases of cytokine release syndrome (CRS), and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS). Correlative biomarkers support application of Descartes-08 in multiple autoimmune diseases observed through a statistically significant (p<0.01) decrease in proinflammatory cytokines associated with SLE p

Forward-Looking Statements

Forward-Looking Statements Any statements in this Current Report on Form 8-K about the future expectations, plans and prospects of the Company, including without limitation, statements regarding the ability of the Company's product candidates to be administered in an outpatient setting or without the need for preconditioning lymphodepleting chemotherapy, the potential of Descartes-08, Descartes-15, or any of the Company's other product candidates to treat myasthenia gravis, juvenile myasthenia gravis, systemic lupus erythematosus, juvenile systemic lupus erythematosus, juvenile dermatomyositis, anti-neutrophil cytoplasmic antibody-associated vasculitis, myositis, or any other disease, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, including the ongoing Phase 3 AURORA trial of Descartes-08 in myasthenia gravis, the planned Phase 2 pediatric basket trial of Descartes-08 in juvenile dermatomyositis, juvenile systemic lupus erythematosus, juvenile myasthenia gravis, and anti-neutrophil cytoplasmic antibody-associated vasculitis, the ongoing Phase 2 trial of Descartes-08 in systemic lupus erythematosus, and the planned Phase 2 trial of Descartes-08 in myositis, the anticipated timing or the outcome of the FDA's review of the Company's regulatory filings, including the number of trials that may be necessary in order to obtain marketing approval, the Company's ability to conduct its clinical trials and preclinical studies, the timing or making of any regulatory filings, the anticipated timing or outcome of selection of developmental product candidates, the novelty of treatment paradigms that the Company is able to develop, the potential of any therapies developed by the Company to fulfill unmet medical needs, and enrollment in the Company's clinical trials and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "hypothesize," "intend," "may," "plan," "potential,

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description 99.1 Press release of Cartesian Therapeutics, Inc. issued on November 1 3 , 2025. 99.2 Corporate slide presentation of Cartesian Therapeutics, Inc. dated November 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARTESIAN THERAPEUTICS, INC. Date: November 13, 2025 By: /s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.